Cadonilimab for recurrent or metastatic cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called cadonilimab in women with cervical cancer that has returned or spread. The goal is to see how well it works in real life and to help manage the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have cervical cancer that has come back (recurred) or spread to other parts of the body (metastatic).
- You cannot have had more than 2 previous treatments for the recurrent or metastatic cancer, unless you have not had any treatment for it yet.
- Your cancer must be one of the following types: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
- You must have at least one tumor that can be measured on imaging scans (like CT or MRI).
- If you are able to get pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial studies a new drug called cadonilimab combined with chemotherapy for women with endometrial cancer that has come back or spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.